Is SERA PROGNOSTICS, INC. (SERA) Halal?

NASDAQ Healthcare United States $72M
✗ NOT HALAL
Confidence: 90/100
SERA PROGNOSTICS, INC. (SERA) is Not Halal under AAOIFI Standard 21. While the debt ratio of 1.1% is acceptable, the cash and interest-bearing securities ratio of 61.4% exceeds the 30% threshold. SERA PROGNOSTICS, INC. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.1%
/ 30%
61.4%
/ 30%
0.1%
/ 30%
3567.53%
/ 5%
✗ NOT HALAL
DJIM 1.1%
/ 33%
61.4%
/ 33%
0.1%
/ 33%
3567.53%
/ 5%
✗ NOT HALAL
MSCI 1.2%
/ 33%
63.7%
/ 33%
0.1%
/ 33%
3567.53%
/ 5%
✗ NOT HALAL
S&P 1.1%
/ 33%
61.4%
/ 33%
0.1%
/ 33%
3567.53%
/ 5%
✗ NOT HALAL
FTSE 1.2%
/ 33%
63.7%
/ 33%
0.1%
/ 50%
3567.53%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.67
P/B Ratio
1.0
EV/EBITDA
-1.0
EV: $36M
Revenue
$77,000
Growth: -58.3%
Beta
1.0
Average volatility
Current Ratio
1.7

Profitability

Gross Margin -102.5%
Operating Margin -89540.0%
Net Margin 0.0%
Return on Equity (ROE) -51.8%
Return on Assets (ROA) -26.1%

Cash Flow & Balance Sheet

Operating Cash Flow-$14M
Free Cash Flow-$15M
Total Debt$840,000
Debt-to-Equity3.1
Current Ratio1.7
Total Assets$73M

Price & Trading

Last Close$1.99
50-Day MA$2.46
200-Day MA$2.85
Avg Volume62K
Beta1.0
52-Week Range
$1.37
$4.09

About SERA PROGNOSTICS, INC. (SERA)

CEO
Ms. Zhenya Lindgardt M.B.A.
Employees
71
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NASDAQ
Market Cap
$72M
Currency
USD

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is SERA PROGNOSTICS, INC. (SERA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), SERA PROGNOSTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is SERA PROGNOSTICS, INC.'s debt ratio?

SERA PROGNOSTICS, INC.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.2%.

What are SERA PROGNOSTICS, INC.'s key financial metrics?

SERA PROGNOSTICS, INC. has a market capitalization of $72M, and revenue of $77,000. Return on equity stands at -51.8%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.